Details

Autor(en) / Beteiligte

• Billié, Stéphan
• Reversé, Kevin
• Arlabosse, Jean-Marie
• Bertin, Didier
• Boulier, Antoine
• Cachot, Tony
• Chambon, Sandrine
• Charras, Karine
• Cren, Cécile
• Furnes, Bjarte
• Gerfaud, Thibaud
• Joly-Battaglini, Marine
• Longoni, Davide
• Mouis, Gregoire
• Pierre, Romain
• Raynard, Héloïse
• Texier, Thomas
• Trognon, Caroline
• Zanelli, Ugo
• Boiteau, Jean-Guy
• Harris, Craig S.

Titel

Identification of unknown impurities J, RRT 2.2, 2.4, 2.6 and 3.4 in tetralysal® capsules

Ist Teil von

• European journal of pharmaceutical sciences, 2023-09, Vol.188, p.106519-106519, Article 106519

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Tetralysal® is a Galderma oral drug product (DP) marketed for the treatment of acne. Tetralysal® is sold in capsules containing either 150 mg or 300 mg of the drug substance. In the British Pharmacopoeia monograph for Lymecycline Capsules, the impurities already specified in the drug substance (A-G), visible in the European Pharmacopoeia 〈1654〉, are also specified together with an unidentified impurity at RRT 1.6 (Impurity J). Based on both monographs Galderma has focused on characterizing most of specified and unspecified impurities to better understand the stability and degradation processes of the formulation. In this manuscript, through both formal synthesis, preparative LCMS and formal degradation studies, we are the first group to confirm the structural identities of 5 unidentified impurities (Impurity J (RRT 1.6), RRT 2.2, 2.4, 2.6 and 3.4), conditions which exacerbate the formation of all 5 impurities and response factors for RRT 2.2, 2.6 and 3.4. [Display omitted]